SLC12A2 Antibody

What are the primary applications for SLC12A2 antibodies in research?

SLC12A2 antibodies are commonly used in Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF/ICC), flow cytometry (FCM), and ELISA applications. According to validation data, these antibodies demonstrate high specificity across various applications, with different products optimized for specific techniques. For most effective results, Western blot applications typically use dilutions ranging from 1:2000-1:10000, while immunohistochemistry typically requires 1:300-1:1200 dilutions . When selecting an antibody, researchers should consider which applications have been validated for each specific product.

What is known about the molecular characteristics of SLC12A2?

SLC12A2 encodes a membrane protein with a molecular weight of approximately 131.4 kDa, though it is typically observed at 150-160 kDa in Western blots due to post-translational modifications . The protein functions as a Na+, K+, 2Cl− cotransporter (NKCC1) and plays critical roles in ionic balance and cell volume regulation. The gene is also known by several aliases including NKCC1, BSC, BSC2, PPP1R141, basolateral Na-K-Cl symporter, and bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1 . SLC12A2 is widely expressed across multiple tissues, unlike the kidney-specific SLC12A1.

How should I prepare samples for optimal SLC12A2 detection?

Sample preparation is critical for successful SLC12A2 detection. For Western blot applications, some antibodies specifically recommend against boiling samples after lysis . For immunohistochemistry, heat-mediated antigen retrieval is typically performed in EDTA buffer (pH 8.0) or alternatively with citrate buffer (pH 6.0) . When working with paraffin-embedded tissue sections, blocking with 10% goat serum followed by overnight incubation with the primary antibody at 4°C produces optimal results . For flow cytometry, fixation with 4% paraformaldehyde and blocking with 10% normal goat serum is recommended before antibody incubation .

How can SLC12A2 antibodies be utilized to study hearing loss mechanisms?

Recent research has identified SLC12A2 variants affecting exon 21 as responsible for hereditary hearing loss in humans . To investigate these mechanisms, researchers can employ SLC12A2 antibodies for immunohistochemistry to analyze protein localization in cochlear tissues. Studies have shown that SLC12A2 is located on the plasma membrane of several cell types in the cochlea, including strial marginal cells critical for endolymph homeostasis . When designing experiments to study hearing loss mechanisms, researchers should prioritize antibodies validated for detecting the carboxy-terminal domain, as variants in this region (particularly exon 21) have been linked to hearing impairment. Functional analysis approaches combining immunohistochemistry with chloride influx assays have been successful in determining how specific mutations affect transporter function.

What approaches are recommended for studying SLC12A2's role in cancer progression?

SLC12A2 has been identified as potentially promoting tumor progression in colorectal cancer (CRC) . When investigating SLC12A2 in cancer models, researchers should consider a multi-faceted approach:

• Expression analysis: Use SLC12A2 antibodies for IHC on cancer tissues to analyze expression patterns and correlate with clinical outcomes

• Functional studies: Combine antibody-based protein detection with siRNA knockdown or plasmid overexpression approaches

• Mechanistic investigations: Examine downstream effects on cancer hallmarks such as proliferation and stemness

Research has shown that SLC12A2 knockdown using siRNA (such as siSLC12A2 #1: TGACCTTATTGATACCTTA or siSLC12A2 #2: GTAAGATCAGAGTATTCAT) restrains proliferation and stemness of CRC cells, while gain-of-function studies showed opposite results . For protein detection in these experiments, researchers have successfully used Western blotting with antibodies from Proteintech (13,884–1-AP) .

What methodologies are appropriate for investigating SLC12A2 variants?

To study SLC12A2 variants, site-directed mutagenesis combined with cell-based functional assays has proven effective. Researchers have successfully created mutant constructs using KAPA Taq EXtra HotStart ReadyMix and confirmed mutations via Sanger sequencing . For functional analysis, transfection of wild-type or mutant plasmids into model cell lines such as HEK-293 cells provides a system to assess protein expression, localization, and morphological differences. Comparing mutant cells with wild-type counterparts can reveal alterations in protein properties and function that indicate pathogenicity. For example, the SLC12A2 [c.2935G>A: p.(E979K)] variant showed different protein expression, localization, and cell morphology from wild-type cells, suggesting altered protein function .

What controls should be included when working with SLC12A2 antibodies?

For robust SLC12A2 antibody experiments, appropriate controls are essential:

• Positive controls: Use tissues or cell lines known to express SLC12A2, such as HeLa cells for Western blotting and IF/ICC , or colon cancer tissue for IHC

• Negative controls: Include isotype control antibodies matched to the primary antibody host species (e.g., rabbit IgG for rabbit polyclonal antibodies)

• Unlabeled sample control: For flow cytometry, include samples without primary and secondary antibody incubation

• siRNA knockdown control: When available, include samples with confirmed SLC12A2 knockdown to verify antibody specificity

• Loading controls: For Western blot, GAPDH has been successfully used in SLC12A2 studies

For flow cytometry specifically, overlay histograms showing cells stained with SLC12A2 antibody versus isotype control and unstained samples provide clear visualization of specific binding .

How should I optimize immunohistochemistry protocols for SLC12A2 detection?

For optimal IHC detection of SLC12A2, follow these methodological steps:

• Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) or citrate buffer (pH 6.0)

• Block tissue sections with 10% goat serum

• Incubate with primary SLC12A2 antibody at 2 μg/ml concentration overnight at 4°C

• Use biotinylated secondary antibody (matching the host species of primary antibody) and incubate for 30 minutes at 37°C

• Develop using Strepavidin-Biotin-Complex (SABC) with DAB as the chromogen

This protocol has been validated for detecting SLC12A2 in various tissues including human colon cancer, rectal cancer, and rat intestine tissues .

What dilution ranges are optimal for different SLC12A2 antibody applications?

Based on validated protocols, optimal dilution ranges for SLC12A2 antibodies vary by application:

These ranges should be optimized for each specific antibody and experimental system. For flow cytometry applications with conjugated antibodies (like APC-conjugated SLC12A2 antibodies), follow manufacturer recommendations as conjugation may affect optimal concentration .

Why might I observe different molecular weights for SLC12A2 in Western blot?

While the predicted molecular weight of SLC12A2 is approximately 131.4 kDa , researchers frequently observe bands at 150-160 kDa in Western blot . This discrepancy is primarily due to post-translational modifications of the protein. Several factors may affect the observed molecular weight:

• Glycosylation state: SLC12A2 undergoes significant glycosylation

• Phosphorylation status: The protein is phosphorylated in response to DNA damage

• Sample preparation methods: Some antibodies specifically recommend against boiling samples after lysis

• Isoform detection: SLC12A2 has three transcript variants encoding two different isoforms

When troubleshooting unexpected band patterns, consider using positive control lysates from tissues known to express SLC12A2 and compare non-boiled versus boiled sample preparation methods.

How can I distinguish between SLC12A2 and related family members?

SLC12A2 (NKCC1) belongs to a family that includes other transporters like SLC12A1 (NKCC2) and SLC12A3. To ensure specificity:

• Select antibodies with validated specificity for SLC12A2, particularly those targeting unique epitopes

• Review the immunogen sequence information - some antibodies target the N-terminus (e.g., residues 223-241) , while others target the C-terminus

• Consider cross-reactivity with other species if working with non-human models

• For functional studies, use selective inhibitors or siRNA approaches to verify antibody specificity

When analyzing tissues expressing multiple SLC family members, complementary approaches such as mRNA analysis may help confirm protein identity. The immunogen sequence homology across species can provide insight into potential cross-reactivity: many SLC12A2 antibodies show 100% sequence homology with dog, pig, rat, horse, mouse, bovine, and rabbit samples, but lower homology with guinea pig (92%) and zebrafish (77%) .

What approaches can help resolve discrepancies in SLC12A2 detection across different techniques?

When faced with contradictory results between different detection methods for SLC12A2:

• Verify antibody validation across the specific applications being used

• Consider tissue-specific expression patterns - SLC12A2 shows differential expression and potentially exon usage across tissues

• Examine potential post-translational modifications that might affect epitope accessibility

• For functional studies, complement protein detection with mRNA analysis and functional assays (e.g., chloride influx measurements)

Research has shown that exon 21-included versus exon 21-skipped SLC12A2 transcripts may be expressed at different levels in specific tissues, suggesting tissue-specific roles for certain protein domains . This could explain discrepancies when using antibodies targeting different regions of the protein across various tissues or experimental conditions.

How can I study the association between SLC12A2 variants and disease phenotypes?

For investigating connections between SLC12A2 variants and disease:

• Begin with genetic analysis to identify candidate variants (e.g., exome sequencing)

• Create expression constructs containing wild-type and mutant SLC12A2 cDNAs

• Perform site-directed mutagenesis to introduce specific variants

• Transfect constructs into appropriate cell lines (HEK-293 cells have been successfully used)

• Use SLC12A2 antibodies to assess protein expression, localization, and morphological changes

• Complement with functional assays such as chloride influx measurements

This approach has successfully demonstrated that SLC12A2 variants affecting exon 21 influence protein function and are associated with hereditary hearing loss . When designing such studies, it's important to note that SLC12A2 is intolerant of functional variation (z score for constraint metric for missense variants is 2.4, and probability of being loss of function-intolerant is 0.96) .

What techniques are effective for studying SLC12A2 in cancer research models?

For cancer-focused SLC12A2 research:

• Establish a prognostic risk model based on SLC12A2 expression in tumor samples

• Use SLC12A2 antibodies for IHC to analyze expression patterns in cancer tissues

• Implement loss-of-function studies through siRNA knockdown

• Conduct gain-of-function studies using SLC12A2 plasmid overexpression

• Assess effects on cancer hallmarks, such as proliferation and stemness

• Use Western blot with antibodies against downstream markers (e.g., C-myc, Nanog, CD44) to evaluate functional consequences

Research has shown that SLC12A2 knockdown restrained proliferation and stemness of colorectal cancer cells, while overexpression promoted these characteristics . This approach can identify potential therapeutic targets and prognostic markers in cancer research.

How should I design experiments to study SLC12A2 phosphorylation?

SLC12A2 is phosphorylated in response to DNA damage , and phosphorylation likely regulates its function. To study this aspect:

• Use phospho-specific antibodies if available, or general phosphorylation detection methods

• Implement treatments known to induce DNA damage to stimulate phosphorylation

• Employ phosphatase inhibitors during sample preparation to preserve phosphorylation status

• Consider immunoprecipitation with SLC12A2 antibodies followed by phosphorylation-specific detection

• Compare migration patterns of phosphorylated versus dephosphorylated protein on Western blot

Since phosphorylation may affect protein function, complement these studies with chloride influx assays to correlate phosphorylation status with transporter activity.